TY - JOUR
T1 - Differential effects of SARS-CoV-2-targeted infection of ATII, club cells, and macrophages on lung immunopathology and antiviral responses
AU - Todd, Austin W.
AU - Shein, Sergey A.
AU - Korchagina, Anna A.
AU - Kudinov, Vasily A.
AU - Faz, Brianna N.
AU - Barre, Ramya S.
AU - Paik, Raehum
AU - Collins, Emma C.
AU - Yusoof, Kizil A.
AU - Khetarpal, Ishana
AU - Weldon, Korri S.
AU - Lai, Zhao
AU - Kurmashev, Dias
AU - Torrelles, Jordi B.
AU - Leadbetter, Elizabeth A.
AU - Xiang, Yan
AU - Chen, Yidong
AU - Martinez-Sobrido, Luis
AU - Koroleva, Ekaterina
AU - Tumanov, Alexei V.
N1 - Publisher Copyright:
© 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Mucosal Immunology. This is an open access article under the CC BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0/
PY - 2026/6
Y1 - 2026/6
N2 - The specific contributions of lung epithelial and immune cells to SARS-CoV-2–induced immunopathology and antiviral responses remain unclear. To address this, we generated mouse models with inducible expression of human angiotensin-converting enzyme 2 (hACE2) in specific lung cell types. Infection of mice expressing hACE2 on club cells triggered early type I interferon responses, limited viral replication, and caused transient, mild lung pathology. In contrast, hACE2-driven infection of type II alveolar epithelial cells (ATIIs) resulted in higher viral loads and moderate lung damage, accompanied by expansion of interstitial macrophages, virus-specific CD8+ T cell responses, and production of anti-SARS-CoV-2 IgG. Additionally, infection of mice expressing hACE2 on ATIIs increased CD11c+ CD8+ effector T cells and proinflammatory cytokines in the lungs, including IFN-γ, CXCL9, and CXCL10. However, neutralization of CXCL9 and CXCL10 exacerbated disease severity. Moreover, infection of mice with hACE2 targeted to ATIIs and macrophages led to severe lung injury, increased viral burden, enhanced T-cell and neutrophil infiltration, higher IgG responses, and sustained lung pathology. In contrast, hACE2 expression limited to endothelial cells was insufficient to promote SARS-CoV-2 replication in the lung or cause pathology. Together, these findings demonstrate that ACE2-driven infection of ATIIs, club cells, and macrophages plays distinct but cooperative roles in driving SARS-CoV-2-induced lung immunopathology and antiviral immunity.
AB - The specific contributions of lung epithelial and immune cells to SARS-CoV-2–induced immunopathology and antiviral responses remain unclear. To address this, we generated mouse models with inducible expression of human angiotensin-converting enzyme 2 (hACE2) in specific lung cell types. Infection of mice expressing hACE2 on club cells triggered early type I interferon responses, limited viral replication, and caused transient, mild lung pathology. In contrast, hACE2-driven infection of type II alveolar epithelial cells (ATIIs) resulted in higher viral loads and moderate lung damage, accompanied by expansion of interstitial macrophages, virus-specific CD8+ T cell responses, and production of anti-SARS-CoV-2 IgG. Additionally, infection of mice expressing hACE2 on ATIIs increased CD11c+ CD8+ effector T cells and proinflammatory cytokines in the lungs, including IFN-γ, CXCL9, and CXCL10. However, neutralization of CXCL9 and CXCL10 exacerbated disease severity. Moreover, infection of mice with hACE2 targeted to ATIIs and macrophages led to severe lung injury, increased viral burden, enhanced T-cell and neutrophil infiltration, higher IgG responses, and sustained lung pathology. In contrast, hACE2 expression limited to endothelial cells was insufficient to promote SARS-CoV-2 replication in the lung or cause pathology. Together, these findings demonstrate that ACE2-driven infection of ATIIs, club cells, and macrophages plays distinct but cooperative roles in driving SARS-CoV-2-induced lung immunopathology and antiviral immunity.
KW - ACE2
KW - Club cells
KW - Macrophages
KW - Mouse models of SARS-CoV-2 disease
KW - SARS-CoV-2
KW - Type II alveolar epithelial cells
UR - https://www.scopus.com/pages/publications/105035237405
UR - https://www.scopus.com/pages/publications/105035237405#tab=citedBy
U2 - 10.1016/j.mucimm.2026.04.001
DO - 10.1016/j.mucimm.2026.04.001
M3 - Article
C2 - 41951100
AN - SCOPUS:105035237405
SN - 1933-0219
VL - 19
JO - Mucosal Immunology
JF - Mucosal Immunology
IS - 3
M1 - 100340
ER -